DOCSLIB.ORG

PRESTWICK Toolbox

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

CPD_ID SUPPLIER CATALOG # CHEMICAL NAME STRUCTURE O N N N PWT000001 PRESTWICK Prestw-1 Azaguanine-8 N H2N N O H2N N O N N PWT000002 PRESTWICK Prestw-2 Allantoin O N N O N S S O PWT000003 PRESTWICK Prestw-3 Acetazolamide H2N O H3C ClH CH HN 3 N N PWT000004 PRESTWICK Prestw-4 Metformin hydrochloride CH H N 3 2 HN O O O O S S O O O O O O H3C CH3 + + H C N O O N CH3 3 O O CH CH PWT000005 PRESTWICK Prestw-5 Atracurium besylate 3 3 O O CH3 O O CH3 H3C CH3 O Chiral O O CH3 CH HO 3 OH CH3 H PWT000006 PRESTWICK Prestw-6 Isoflupredone acetate F H O ClH OH 2 OH2 O NH Cl N N NH PWT000007 PRESTWICK Prestw-7 Amiloride hydrochloride dihydrate 2 H2N N NH2 Cl ClH N CH3 N + NH N 2 CH PWT000008 PRESTWICK Prestw-8 Amprolium hydrochloride 3 O O O NH2 S S N O PWT000009 PRESTWICK Prestw-9 Hydrochlorothiazide N Cl O O S NH H N N PWT000010 PRESTWICK Prestw-10 Sulfaguanidine 2 NH2 O O O H N 2 S S O PWT000011 PRESTWICK Prestw-11 Meticrane H3C O O O 9CH3 H C N PWT000012 PRESTWICK Prestw-12 Benzonatate 3 F F F N O N PWT000013 PRESTWICK Prestw-13 Hydroflumethiazide S S H N 2 O O O OH2 Na O H2N N PWT000014 PRESTWICK Prestw-14 Sulfacetamide sodic hydrate S CH O 3 O ClH HO NH PWT000015 PRESTWICK Prestw-15 Heptaminol hydrochloride 2 H3C CH3 CH3 N H N 2 N S S PWT000016 PRESTWICK Prestw-16 Sulfathiazole O O O Chiral OH NH2 PWT000017 PRESTWICK Prestw-17 Levodopa HO OH I Chiral O O N N PWT000018 PRESTWICK Prestw-18 Idoxuridine HO O HO Chiral O N OH H C 3 O PWT000019 PRESTWICK Prestw-19 Captopril HS H2N HO N N PWT000020 PRESTWICK Prestw-20 Minoxidil N HN NH2 N N PWT000021 PRESTWICK Prestw-21 Sulfaphenazole N S O O OH Chiral HO N OH H3C PWT000022 PRESTWICK Prestw-22 Panthenol (D) CH3 O N H N 2 N S N PWT000023 PRESTWICK Prestw-23 Sulfadiazine O O CH Chiral CH3 OH H PWT000024 PRESTWICK Prestw-24 Norethynodrel H H O Cl OH Chiral N Cl O O PWT000025 PRESTWICK Prestw-25 Thiamphenicol HO S CH O 3 S N N N N H C 3 N PWT000026 PRESTWICK Prestw-26 Cimetidine N CH3 O O OH HO N H C O PWT000027 PRESTWICK Prestw-27 Doxylamine succinate 3 N H3C CH3 ClH ClH HO Chiral H C N 3 N CH PWT000028 PRESTWICK Prestw-28 Ethambutol dihydrochloride 3 OH H3C N CH3 N PWT000029 PRESTWICK Prestw-29 Antipyrine O H3C CH N 3 N PWT000030 PRESTWICK Prestw-30 Antipyrine, 4-hydroxy OH O Cl Cl Chiral O + N O N O PWT000031 PRESTWICK Prestw-31 Chloramphenicol OH OH CH O 3 H C 3 O N N N CH3 PWT000032 PRESTWICK Prestw-32 Epirizole N H3C O CH3 N HO O N PWT000033 PRESTWICK Prestw-33 Diprophylline HO N N CH3 NH N 2 N H2N N N PWT000034 PRESTWICK Prestw-34 Triamterene NH2 H2N NH2 PWT000035 PRESTWICK Prestw-35 Dapsone S O O O Chiral H3C O CH3 CH H3C O 3 O O CH3 CH3 H3C H3C O O N H3C O CH3 O O CH3 O O CH3 H C O PWT000036 PRESTWICK Prestw-36 Troleandomycin 3 H3C O O Cl NH2 N N NH PWT000037 PRESTWICK Prestw-37 Pyrimethamine 2 CH3 Br Br OH2 OH2 H3C H3C + + CH3 PWT000038 PRESTWICK Prestw-38 Hexamethonium dibromide dihydrate N N H3C CH3 CH3 O HO F PWT000039 PRESTWICK Prestw-39 Diflunisal HO F OH O Cl O + PWT000040 PRESTWICK Prestw-40 Niclosamide N N Cl O ClH CH O 3 N CH O 3 PWT000041 PRESTWICK Prestw-41 Procaine hydrochloride H2N O CH3 CH3 O ClH O H C CH PWT000042 PRESTWICK Prestw-42 Moxisylyte hydrochoride 3 3 N H3C CH3 ClH ClH N N PWT000043 PRESTWICK Prestw-43 Betazole hydrochloride NH2 O O S CH N 3 N N O PWT000044 PRESTWICK Prestw-44 Isoxicam OH O CH3 H3C O CH3 PWT000045 PRESTWICK Prestw-45 Naproxen O OH ClH N N PWT000046 PRESTWICK Prestw-46 Naphazoline hydrochloride ClH Cl S PWT000047 PRESTWICK Prestw-47 Ticlopidine hydrochloride N H C ClH O 3 N O CH3 PWT000048 PRESTWICK Prestw-48 Dicyclomine hydrochloride ClH H3C O H3C PWT000049 PRESTWICK Prestw-49 Amyleine hydrochloride O N CH3 H3C ClH CH CH3 3 N PWT000050 PRESTWICK Prestw-50 Lidocaine hydrochloride N O H C CH3 3 OH Chiral HO H O O H C O H C 3 3 O H OH H C PWT000051 PRESTWICK Prestw-1795 Mupirocin 3 OH O N PWT000052 PRESTWICK Prestw-52 Carbamazepine H2N O ClH F F S F N H C PWT000053 PRESTWICK Prestw-53 Triflupromazine hydrochloride 3 N H3C HO CH3 O H C 3 N PWT000054 PRESTWICK Prestw-54 Mefenamic acid H3C O N N S PWT000055 PRESTWICK Prestw-55 Acetohexamide O O O O N N O CH CH 3 O 3 PWT000056 PRESTWICK Prestw-56 Sulpiride S H N 2 O ClH O H2N O CH3 O N CH PWT000057 PRESTWICK Prestw-57 Benoxinate hydrochloride 3 H3C OH N O O H C CH 3 N N 3 PWT000058 PRESTWICK Prestw-58 Oxethazaine CH 3 H3C CH 3 H3C OH O O OH PWT000059 PRESTWICK Prestw-59 Pheniramine maleate N N H3C CH3 ClH PWT000060 PRESTWICK Prestw-60 Tolazoline hydrochloride N N O OH HO OH HO O CH3 N N PWT000061 PRESTWICK Prestw-61 Morantel tartrate S H3C BrH H3C N H O PWT000062 PRESTWICK Prestw-62 Homatropine hydrobromide (R,S) O H OH H3C N CH3 O O CH H3C 3 O O + PWT000063 PRESTWICK Prestw-63 Nifedipine N O O ClH Cl S H C PWT000064 PRESTWICK Prestw-64 Chlorpromazine hydrochloride 3 N N H3C ClH H3C N O H C PWT000065 PRESTWICK Prestw-65 Diphenhydramine hydrochloride 3 ClH ClH O N N N PWT000066 PRESTWICK Prestw-66 Minaprine dihydrochloride N CH3 Cl Cl Cl O PWT000067 PRESTWICK Prestw-67 Miconazole N Cl N ClH OH N PWT000068 PRESTWICK Prestw-68 Isoxsuprine hydrochloride HO O H3C H3C ClH H3C N CH3 OH O O PWT000069 PRESTWICK Prestw-69 Acebutolol hydrochloride O H3C N CH3 CH3 N O H3C PWT000070 PRESTWICK Prestw-70 Tolnaftate S ClH O N H C O PWT000071 PRESTWICK Prestw-71 Todralazine hydrochloride 3 N N N ClH H C PWT000072 PRESTWICK Prestw-72 Imipramine hydrochloride 3 N N H3C CH3 S O CH3 Prestw-73 Sulindac O PWT000073 PRESTWICK F OH ClH H3C PWT000074 PRESTWICK Prestw-74 Amitryptiline hydrochloride N H3C ClH CH3 O PWT000075 PRESTWICK Prestw-75 Adiphenine hydrochloride N O CH3 CH3 O H3C N N N H C Prestw-76 Dibucaine 3 PWT000076 PRESTWICK O OHChiral O CH OH O 3 CH3 H PWT000077 PRESTWICK Prestw-77 Prednisone H H O ClH CH3 S CH 3 S N PWT000078 PRESTWICK Prestw-78 Thioridazine hydrochloride N CH O 3 O S O O CH3 + PWT000079 PRESTWICK Prestw-79 Diphemanil methylsulfate N CH3 ClH O H C 3 N O O PWT000080 PRESTWICK Prestw-80 Trimethobenzamide hydrochloride H3C N O CH3 O H3C CH3 O + N O N N PWT000081 PRESTWICK Prestw-81 Metronidazole HO CH3 OH CH3 Chiral H O H H F F S F HO F PWT000082 PRESTWICK Prestw-1424 Fulvestrant F Cl H3C + PWT000083 PRESTWICK Prestw-83 Edrophonium chloride HO N CH3 H3C ClH HN HN PWT000084 PRESTWICK Prestw-84 Moroxidine hydrochloride N N O H2N Cl O PWT000085 PRESTWICK Prestw-85 Baclofen (R,S) H2N OH NH2 N HO N O N PWT000086 PRESTWICK Prestw-86 Acyclovir N O N CH3 N Cl S PWT000087 PRESTWICK Prestw-87 Diazoxide O O H3C CH3 N N CH3 N PWT000088 PRESTWICK Prestw-88 Amidopyrine O CH3 O H C O 3 O S S O O PWT000089 PRESTWICK Prestw-1179 Busulfan CH3 O CH3 H3C N OH O PWT000090 PRESTWICK Prestw-90 Pindolol N H C 3 O O O PWT000091 PRESTWICK Prestw-91 Khellin O H3C O CH3 ClH OH2 ClH Br CH3 N CH PWT000092 PRESTWICK Prestw-92 Zimelidine dihydrochloride monohydrate 3 N OH PWT000093 PRESTWICK Prestw-93 Azacyclonol N O + N N O N S H3C PWT000094 PRESTWICK Prestw-94 Azathioprine N N N N CH Chiral CH3 OH H H PWT000095 PRESTWICK Prestw-95 Lynestrenol H H O H3C OH N NH2 Cl N PWT000096 PRESTWICK Prestw-96 Guanabenz acetate NH Cl S CH3 H3C S N S N CH3 PWT000097 PRESTWICK Prestw-97 Disulfiram H C 3 S O O HO PWT000098 PRESTWICK Prestw-98 Acetylsalicylsalicylic acid O O H3C O ClH PWT000099 PRESTWICK Prestw-99 Mianserine hydrochloride N N CH3 N N S O N H C PWT000100 PRESTWICK Prestw-100 Nocodazole 3 O O ClH OH2 ClH Chiral N CH3 H N HO CH3 H Prestw-101 R(-) Apomorphine hydrochloride hemihydrate HO PWT000101 PRESTWICK HO HO N N N PWT000102 PRESTWICK Prestw-102 Amoxapine Cl O ClH H C N PWT000103 PRESTWICK Prestw-103 Cyproheptadine hydrochloride 3 S N N H2N S NH NH2 N O PWT000104 PRESTWICK Prestw-104 Famotidine S O NH2 CHChiral HO H3C CH3 H PWT000105 PRESTWICK Prestw-105 Danazol N H H O O O + O N N PWT000106 PRESTWICK Prestw-106 Nicorandil O N CH3 N N O O PWT000107 PRESTWICK Prestw-1314 Pioglitazone S O O OH O OH N PWT000108 PRESTWICK Prestw-108 Nomifensine maleate CH3 NH2 O OH HO O CH3 Chiral CH3 O O O NH2 O O H C PWT000109 PRESTWICK Prestw-1810 Aliskiren hemifumarate 3 N NH2 H C CH3 OH 3 CH3 H3C CH3 Chiral OHCH CH3 3 H CH3 O PWT000110 PRESTWICK Prestw-1192 Oxandrolone H H O H ClH CH Chiral N 2 OH PWT000111 PRESTWICK Prestw-111 Naloxone hydrochloride HO O O Cl N CH3 O N S H2N PWT000112 PRESTWICK Prestw-112 Metolazone O O H3C ClH OH2 O O F OH PWT000113 PRESTWICK Prestw-113 Ciprofloxacin hydrochloride monohydrate N N N OH OH2 OH2 2 Chiral N S H2N CH3 O N CH PWT000114 PRESTWICK Prestw-114 Ampicillin trihydrate 3 O O HO Cl O F PWT000115 PRESTWICK Prestw-115 Haloperidol N HO OH2 OH2 ClH N Chiral OH PWT000116 PRESTWICK Prestw-116 Naltrexone hydrochloride dihydrate HO O O O OH O OH H C CH3 3 N PWT000117 PRESTWICK Prestw-117 Chlorpheniramine maleate N Cl ClH Chiral N OH PWT000118 PRESTWICK Prestw-118 Nalbuphine hydrochloride HO O OH OH2 O N N H C O N PWT000119 PRESTWICK Prestw-119 Picotamide monohydrate 3 O N HO Chiral HO CH3 HO O CH3 H OH PWT000120 PRESTWICK Prestw-120 Triamcinolone F H O O H3C S OH O CH3 Chiral OH H3C O N O N H N O O CH3 N CH3 CH PWT000121 PRESTWICK Prestw-121 Bromocryptine mesylate H 3 N Br ClH CH3 H3C PWT000122 PRESTWICK Prestw-1471 Amfepramone hydrochloride N H C 3 O O Chiral H3C OH O CH3 CH3 H PWT000123 PRESTWICK Prestw-123 Dehydrocholic acid H H O O H S Cl O Cl PWT000124 PRESTWICK Prestw-1184 Tioconazole N N Cl HO N N PWT000125 PRESTWICK Prestw-125 Perphenazine N Cl S ClH HO N F PWT000126 PRESTWICK Prestw-126 Mefloquine hydrochloride N F F F F F N N Cl PWT000127 PRESTWICK Prestw-127 Isoconazole O Cl Cl Cl O Chiral O H3C CH3 H O PWT000128 PRESTWICK Prestw-128 Spironolactone H H O S CH3 ClH ClH N N N N O N H3C PWT000129 PRESTWICK
Recommended publications

  • (12) United States Patent (10) Patent No.: US 7,871,995 B2 Bunschoten Et Al

    US00787 1995 B2 (12) United States Patent (10) Patent No.: US 7,871,995 B2 Bunschoten et al. (45) Date of Patent: *Jan. 18, 2011 (54) DRUG DELIVERY SYSTEM COMPRISINGA (52) U.S. Cl. ....................................... 514/171; 514/182 TETRAHYDROXYLATED ESTROGEN FOR (58) Field of Classification Search ................. 514/171, USE IN HORMONAL CONTRACEPTION 514f182 See application file for complete search history. (75) Inventors: Evert Johannes Bunschoten, Heesch (NL); Herman Jan Tijmen Coelingh (56) References Cited Bennink, Driebergen (NL); Christian U.S. PATENT DOCUMENTS Franz Holinka, New York, NY (US) 3,440,320 A 4, 1969 Sackler et al. O O 3,797.494. A 3, 1974 Zaffaroni (73) Assignee: Pantarhei Bioscience B.V., Al Zeist 4,460.372 A 7/1984 Campbell et al. (NL) 4,573.996 A 3/1986 Kwiatek et al. 4,624,665 A 1 1/1986 Nuwayser (*) Notice: Subject to any disclaimer, the term of this 4,722,941 A 2f1988 Eckert et al. patent is extended or adjusted under 35 4,762,717 A 8/1988 Crowley, Jr. U.S.C. 154(b) by 1233 days. 4.937,238 A 6, 1990 Lemon 5,063,507 A 1 1/1991 Lindsey et al. This patent is Subject to a terminal dis- 5,130,137 A 7/1992 Crowley, Jr. claimer. 5,211,952 A 5/1993 Spicer et al. 5,223,261 A 6/1993 Nelson et al. 5,340,584 A 8/1994 Spicer et al. (21) Appl. No.: 10/478,357 5,340,585 A 8/1994 Pike et al. 1-1. 5,340,586 A 8, 1994 Pike et al.
  • The National Drugs List

    The National Drugs List

    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
  • ELECTRONIC CLAIMS MANAGEMENT ENGINE (ECME) Version 1.0

    ELECTRONIC CLAIMS MANAGEMENT ENGINE (ECME) Version 1.0

    ELECTRONIC CLAIMS MANAGEMENT ENGINE (ECME) Version 1.0 USER MANUAL December 2020 Department of Veterans Affairs Office of Information and Technology (OIT) Product Development Revision History Date Description (Patch # if applicable) Project Manager Technical Writer 12/2020 Updated for BPS*1*27 MCCF EDI TAS MCCF EDI TAS Updated Potential Secondary Rx Claims Report ePharmacy ePharmacy Screen Display Development TeamDevelopment Team Updated Title Page date and footers 04/2020 Updated for BPS*1*26 REDACTED REDACTED Updated section 5.6 Add/View Comments Updated Title Page date and footers 1/2019 Updated for BPS*1*24 REDACTED REDACTED Change label on Claim Log, Modify Change View (CV), Enhance Claim Reports 08/2018 Updated for BPS*1*23 REDACTED REDACTED Update Title page date, footer date Modification filter questions CV Change View action, Rx Activity Log to add Date of Service to ECME Log, Resubmit with Edits action, Process Secondary/TRICARE Rx to ECME option, Payable Claims Report, Rejected Claims Report, Reversal Claims Report, Claims Submitted Not Yet Released Report, Recent Transactions Report, Closed Claims Report, View ePharmacy Rx Report Option 11/2017 Updated for BPS*1*22 REDACTED REDACTED Update Title page date, modification to Change View action; change auto-reverse parameter and auto-reversal bulletin; add Facility ID Qualifier and Reconciliation ID to Claim Log and Claim Response Inquiry; add new action PR Print Reports to VER View ePharmacy Rx. 05/2017 Updated for BPS*1*21 REDACTED REDACTED 08/2016 Updated for BPS*1*20 REDACTED
  • Muscarinic Acetylcholine Receptor

    Muscarinic Acetylcholine Receptor

    mAChR Muscarinic acetylcholine receptor mAChRs (muscarinic acetylcholine receptors) are acetylcholine receptors that form G protein-receptor complexes in the cell membranes of certainneurons and other cells. They play several roles, including acting as the main end-receptor stimulated by acetylcholine released from postganglionic fibersin the parasympathetic nervous system. mAChRs are named as such because they are more sensitive to muscarine than to nicotine. Their counterparts are nicotinic acetylcholine receptors (nAChRs), receptor ion channels that are also important in the autonomic nervous system. Many drugs and other substances (for example pilocarpineand scopolamine) manipulate these two distinct receptors by acting as selective agonists or antagonists. Acetylcholine (ACh) is a neurotransmitter found extensively in the brain and the autonomic ganglia. www.MedChemExpress.com 1 mAChR Inhibitors & Modulators (+)-Cevimeline hydrochloride hemihydrate (-)-Cevimeline hydrochloride hemihydrate Cat. No.: HY-76772A Cat. No.: HY-76772B Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other… gastrointestinal, urinary, and reproductive systems and other… Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 mg, 5 mg 1 mg, 5 mg AC260584 Aclidinium Bromide Cat. No.: HY-100336 (LAS 34273; LAS-W 330) Cat.
  • Réglementation De La Pharmacie

    Réglementation De La Pharmacie

    R E C U E I L D E T E X T E S S U R L A P H A R M A C I E Mis à jour le 13 février 2017 par l’Inspection de la pharmacie P R É A M B U L E La réglementation relative à la pharmacie en vigueur en Nouvelle-Calédonie résulte de la coexistence des dispositions adoptées par la Nouvelle-Calédonie au titre de ses compétences en matières d’hygiène publique, de santé et de professions de la pharmacie1, et de celles adoptées par l’Etat au titre de ses compétences en matières de garanties des libertés publiques, de droit civil et de droit commercial2. Sur le contenu du recueil En 1954, la Nouvelle-Calédonie s’est vue étendre les articles L. 511 à L. 520 et L. 549 à L. 665 de l’ancien Livre V relatif à la Pharmacie du code de la santé publique métropolitain par la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du Code de la santé publique relatives à l'exercice de la pharmacie3, dont les modalités d’application ont été fixées par le décret modifié n° 55-1122 du 16 août 1955 fixant les modalités d'application de la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du code de la santé publique relatives à l'exercice de la pharmacie4. Depuis sont intervenues la loi- cadre Defferre5, la loi référendaire de 19886 et la loi organique n° 99-209 du 19 mars 1999 dont les apports ont eu pour résultat le transfert de ces articles de la compétence de l’Etat à la compétence de la Nouvelle-Calédonie, permettant à celle-ci de s’en approprier et de les modifier à sa guise par des délibérations du congrès de la Nouvelle-Calédonie7.
  • Rodgers 693..696

    Rodgers 693..696

    Copyright #ERS Journals Ltd 1999 Eur Respir J 1999; 14: 693±696 European Respiratory Journal Printed in UK ± all rights reserved ISSN 0903-1936 The effect of topical benzamil and amiloride on nasal potential difference in cystic fibrosis H.C. Rodgers, A.J. Knox The effect of topical benzamil and amiloride on nasal potential difference in cystic fibrosis. Respiratory Medicine Unit, City Hospital, H.C. Rodgers, A.J. Knox. #ERS Journals Ltd 1999. Hucknall Road, Nottingham, NG5 IPB. ABSTRACT: The electrochemical defect in the bronchial epithelium in cystic fibrosis (CF) consists of defective chloride secretion and excessive sodium reabsorption. The Correspondence: A.J. Knox Respiratory Medicine Unit sodium channel blocker, amiloride, has been shown to reversibly correct the sodium Clinical Sciences Building reabsorption in CF subjects, but long term studies of amiloride have been disap- City Hospital pointing due to its short duration of action. Benzamil, a benzyl substituted amiloride Hucknall Road analogue, has a longer duration of action than amiloride in cultured human nasal Nottingham NG5 lPB epithelium. The results of the first randomized, placebo controlled, double blind, UK crossover study are reported here comparing the effects of benzamil and amiloride on Fax: 0115 9602140 nasal potential difference (nasal PD) in CF. Ten adults with CF attended on three occasions. At each visit baseline nasal PD was Keywords: Amiloride -3 -3 benzamil recorded, the drug (amiloride 1610 M, benzamil 1.7610 M, or 0.9% sodium cystic fibrosis chloride) was administered topically via a nasal spray, and nasal PD was measured at nasal potential difference 15, 30 min, 1, 2, 4 and 8 h.
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
  • 4 Supplementary File

    4 Supplementary File

    Supplemental Material for High-throughput screening discovers anti-fibrotic properties of Haloperidol by hindering myofibroblast activation Michael Rehman1, Simone Vodret1, Luca Braga2, Corrado Guarnaccia3, Fulvio Celsi4, Giulia Rossetti5, Valentina Martinelli2, Tiziana Battini1, Carlin Long2, Kristina Vukusic1, Tea Kocijan1, Chiara Collesi2,6, Nadja Ring1, Natasa Skoko3, Mauro Giacca2,6, Giannino Del Sal7,8, Marco Confalonieri6, Marcello Raspa9, Alessandro Marcello10, Michael P. Myers11, Sergio Crovella3, Paolo Carloni5, Serena Zacchigna1,6 1Cardiovascular Biology, 2Molecular Medicine, 3Biotechnology Development, 10Molecular Virology, and 11Protein Networks Laboratories, International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 34149, Trieste, Italy 4Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy 5Computational Biomedicine Section, Institute of Advanced Simulation IAS-5 and Institute of Neuroscience and Medicine INM-9, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany 6Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy 7National Laboratory CIB, Area Science Park Padriciano, Trieste, 34149, Italy 8Department of Life Sciences, University of Trieste, Trieste, 34127, Italy 9Consiglio Nazionale delle Ricerche (IBCN), CNR-Campus International Development (EMMA- INFRAFRONTIER-IMPC), Rome, Italy This PDF file includes: Supplementary Methods Supplementary References Supplementary Figures with legends 1 – 18 Supplementary Tables with legends 1 – 5 Supplementary Movie legends 1, 2 Supplementary Methods Cell culture Primary murine fibroblasts were isolated from skin, lung, kidney and hearts of adult CD1, C57BL/6 or aSMA-RFP/COLL-EGFP mice (1) by mechanical and enzymatic tissue digestion. Briefly, tissue was chopped in small chunks that were digested using a mixture of enzymes (Miltenyi Biotec, 130- 098-305) for 1 hour at 37°C with mechanical dissociation followed by filtration through a 70 µm cell strainer and centrifugation.
  • Electronic Claims Management Version 1.0 Engine User Manual

    Electronic Claims Management Version 1.0 Engine User Manual

    Electronic Claims Management Engine (ECME) Version 1.0 User Manual May 2021 Department of Veterans Affairs Office of Information and Technology (OIT) Revision History Description (Patch # if Date Project Manager Technical Writer applicable) 05/2021 Updated for BPS*1*28 MCCF EDI TAS MCCF EDI TAS Updated Title Page date and ePharmacy ePharmacy footers Development Development Added Section 6.3.3 SC Team Team Prescriptions for Active Duty Prescriptions Added Section 8.1.11 Duplicate Claims Report 12/2020 Updated for BPS*1*27 MCCF EDI TAS MCCF EDI TAS Updated Potential Secondary Rx ePharmacy ePharmacy Claims Report Screen Display Development Development Updated Title Page date and Team Team footers 04/2020 Updated for BPS*1*26 REDACTED REDACTED Updated section 5.6 Add/View Comments Updated Title Page date and footers 1/2019 Updated for BPS*1*24 REDACTED REDACTED Change label on Claim Log, Modify Change View (CV), Enhance Claim Reports 08/2018 Updated for BPS*1*23 REDACTED REDACTED Update Title page date, footer date Modification filter questions CV Change View action, Rx Activity Log to add Date of Service to ECME Log, Resubmit with Edits action, Process Secondary/TRICARE Rx to ECME option, Payable Claims Report, Rejected Claims Report, Reversal Claims Report, Claims Submitted Not Yet Released Report, Recent Transactions Report, Closed Claims Report, View ePharmacy Rx Report Option Electronic Claims Management Engine V. 1.0 User Manual ii May 2021 Description (Patch # if Date Project Manager Technical Writer applicable) 11/2017 Updated for BPS*1*22 REDACTED REDACTED Update Title page date, modification to Change View action; change auto-reverse parameter and auto-reversal bulletin; add Facility ID Qualifier and Reconciliation ID to Claim Log and Claim Response Inquiry; add new action PR Print Reports to VER View ePharmacy Rx.
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1

    Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1

    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
  • The Inhaled Steroid Ciclesonide Blocks SARS-Cov-2 RNA Replication by Targeting Viral

    The Inhaled Steroid Ciclesonide Blocks SARS-Cov-2 RNA Replication by Targeting Viral

    bioRxiv preprint doi: https://doi.org/10.1101/2020.08.22.258459; this version posted August 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting viral 2 replication-transcription complex in culture cells 3 4 Shutoku Matsuyamaa#, Miyuki Kawasea, Naganori Naoa, Kazuya Shiratoa, Makoto Ujikeb, Wataru 5 Kamitanic, Masayuki Shimojimad, and Shuetsu Fukushid 6 7 aDepartment of Virology III, National Institute of Infectious Diseases, Tokyo, Japan 8 bFaculty of Veterinary Medicine, Nippon Veterinary and Life Science University, Tokyo, Japan 9 cDepartment of Infectious Diseases and Host Defense, Gunma University Graduate School of 10 Medicine, Gunma, Japan 11 dDepartment of Virology I, National Institute of Infectious Diseases, Tokyo, Japan. 12 13 Running Head: Ciclesonide blocks SARS-CoV-2 replication 14 15 #Address correspondence to Shutoku Matsuyama, [email protected] 16 17 Word count: Abstract 149, Text 3,016 bioRxiv preprint doi: https://doi.org/10.1101/2020.08.22.258459; this version posted August 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 18 Abstract 19 We screened steroid compounds to obtain a drug expected to block host inflammatory responses and 20 MERS-CoV replication. Ciclesonide, an inhaled corticosteroid, suppressed replication of MERS-CoV 21 and other coronaviruses, including SARS-CoV-2, the cause of COVID-19, in cultured cells. The 22 effective concentration (EC90) of ciclesonide for SARS-CoV-2 in differentiated human bronchial 23 tracheal epithelial cells was 0.55 μM.
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).